Navigation Links
Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
Date:5/30/2012

THE WOODLANDS, Texas, May 30, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer, will present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6 at 11:00 a.m. Eastern Time in New York City. Dr. Zambrowicz will provide an overview of Lexicon's clinical development programs and milestones.

A live webcast of the presentation will be available through Lexicon's corporate website at www.lexpharma.com. An archived version of the presentation will be available for 30 days after the event.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has five drug programs in mid-stage development for diabetes, carcinoid syndrome, irritable bowel syndrome, rheumatoid arthritis and glaucoma, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon to Provide First Quarter 2012 Financial Results
4. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
5. Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
6. Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
7. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Lexicon Announces Commencement of Rights Offering to Stockholders
9. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
10. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
11. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... India , February 10, 2016 ... The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic ... Trends, Technologies, Participants, and Environment" research report indicates ... worth over $149 billion by 2020 growing at ... up of companion diagnostics and targeted therapeutics and ...
(Date:2/10/2016)... LONDON , February 10, 2016 ... window and M 1 receptor selectivity   ... Heptares StaR® technology, which has entered clinical development ... patients with dementia and schizophrenia.   --> ... StaR® technology, which has entered clinical development as ...
(Date:2/9/2016)... Feb. 9, 2016  Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... cosmetic surgery, laparoscopic surgery and other surgical applications, ... and the first half of fiscal year 2016 ... --> --> Highlights for the ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... , ... Gout is like no other joint pain. It strikes suddenly, like ... swelling and redness. It is triggered by the crystallization of uric acid within the ... susceptible, according to the February 2016 issue of Harvard Men's Health Watch. , The ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis ... Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning author ... memory. The book’s publication date is March 16, 2016. A free review copy ...
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... Florida – 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & ... 27th: Elite Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for ... FHU President Joe Wiley made the announcement Monday night, Feb. 8, prior to the ... graduate of FHU and the creator of GO! Camp, has been named director. Gayle ...
(Date:2/10/2016)... ... February 10, 2016 , ... It’s that time of year when most people ... the Interscholastic Athletic Association of Maryland (IAAM), Hall of Fame athlete and Garrison Forest ... cast aside. , That’s why one of her first decisions when her IAAM two-year ...
Breaking Medicine News(10 mins):